Tempest Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Tempest Therapeutics, Inc. (TPST) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.24 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2021-03-29
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2012-12-31 was $523.00K.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $4.24M, a 1.69% decline from fiscal 2019.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $4.32M, a 202.52% increase from fiscal 2018.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $1.43M, a 79.30% decline from fiscal 2017.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $6.89M, a 25.20% decline from fiscal 2016.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.24M 10-K · filed 2021-03-29 | |||
| 2019-12-31 | $4.32M 10-K · filed 2021-03-29 | |||
| 2018-12-31 | $1.43M 10-K · filed 2020-03-11 | |||
| 2017-12-31 | $6.89M 10-K · filed 2018-03-15 | |||
| 2016-12-31 | $9.21M 10-K · filed 2018-03-15 | |||
| 2015-12-31 | $19.34M 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $12.41M 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $5.09M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.38M 10-K · filed 2015-03-16 | ||
| 2012-09-30 | $859.00K 10-Q · filed 2012-11-13 | |||
| 2011-12-31 | $347.00K 10-K · filed 2014-02-27 | $346.00K 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |